AGP Executive Report
Last update: 9 hours agoRett syndrome breakthrough: The EU’s CHMP has reversed course and issued a positive opinion for Neuren’s DAYBU (trofinetide), recommending marketing authorisation for neurobehavioral symptoms of Rett syndrome in adults and children aged five and older—if the European Commission follows through, it would be the first EU-approved therapy for this indication, with Acadia leading commercialisation. Cancer care advances: The European Commission also approved Gilead’s Trodelvy as first-line monotherapy for unresectable or metastatic triple-negative breast cancer in patients not eligible for PD-1/PD-L1 inhibitors, and approved Merck/MSD’s Keytruda plus Padcev perioperatively for cisplatin-ineligible muscle-invasive bladder cancer, aiming to reduce recurrence and death risk. Public health basics: A new global map highlights that more than 2 billion people still lack safely managed drinking water, showing big gaps even where access is near-universal. Heat and health: Europe’s heatwave is forcing schools to close or shorten days due to limited cooling in classrooms, raising concerns for child safety.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
